fig9

Figure 9. (A) Prognosis of low and high expression levels of hsa-mir-1286a in grade 4 gliomas; (B) Expression of hsa-mir-1286a was detected using RT-qPCR (^*P < 0.05, ^**P < 0.01 vs. control group); (C) Expression of hsa-mir-1286a after using hsa-miR-1286a inhibitor was detected using RT-qPCR (^**P < 0.01 vs. control group); (D) Cell viability of U251 cells after 24 h of TMZ treatment after microFF hsa-miR-1286 inhibitor added (^****P < 0.0001 vs. control group). RT-qPCR: Reverse transcription-quantitative polymerase chain reaction; TMZ: temozolomide.